Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- Amgen (AMGN) delivered double-digit revenue growth in its latest fiscal year and now counts 14 products with more than $1 billion in annual sales, reflecting a broader, more diversified portfolio.
- Biogen (BIIB) continues to manage revenue declines in its legacy multiple sclerosis (MS) franchise while its newer medicines, including Leqembi and Skyclarys, grow quickly.
- Both companies face patent and competitive pressure, but Amgen is absorbing biosimilar erosion while expanding, whereas Biogen is still transitioning toward its "New Biogen" pipeline.
- Amgen's obesity candidate MariTide and Biogen's Alzheimer's and lupus programs are the key forward-looking catalysts shaping sentiment for each stock.
- On trend consistency and relative positioning, Amgen currently screens as the more stable large-cap, while Biogen offers greater optionality tied to clinical readouts.
Introduction
Amgen and Biogen are two of the most recognized names in biotechnology, yet they sit at very different stages of their growth cycles. Amgen has leveraged a diversified portfolio spanning inflammation, oncology, rare disease, and cardiometabolic therapies to deliver consistent expansion, while Biogen is working to offset the erosion of its once-dominant MS franchise with a wave of newer launches. This stock comparison is relevant for investors weighing a steadier, income-generating large-cap against a value-oriented name with catalyst-driven optionality. Understanding their relative performance, growth drivers, and risk profiles can help clarify which market positioning better suits a given trading or investing approach.
AMGN Overview and Recent Performance
AMGN (Amgen) is a global biotechnology leader that discovers, develops, and commercializes therapies across inflammation, oncology, rare disease, and cardiovascular care. In recent quarters, the company has posted strong operational results, including 10% revenue growth for its latest fiscal year and 14 blockbuster products surpassing $1 billion in annual sales. Growth has been powered by medicines such as Repatha (for cholesterol), Evenity (for osteoporosis), and Tezspire (for severe asthma), each expanding by more than 30% year over year. Sentiment has also been shaped by MariTide, Amgen's late-stage obesity candidate, which investors view as a potentially differentiated, longer-interval dosing option. Offsetting this momentum, patents for Prolia and Xgeva expired in early 2025, and management expects accelerating biosimilar (near-identical biologic copies) competition to erode those sales in 2026. Amgen has also raised its dividend for 14 consecutive years, reinforcing its appeal to income-focused investors.
BIIB Overview and Recent Performance
BIIB (Biogen) is a neuroscience-focused biotechnology company historically defined by its MS portfolio, including Tecfidera and Tysabri. In recent market activity, the company has reported declining total revenue, down about 7% year over year in its latest quarter, driven primarily by generic and competitive pressure on its legacy MS drugs. At the same time, its newer growth products have shown momentum: Leqembi (lecanemab), an Alzheimer's disease therapy developed with Eisai, continues to gain share, while Skyclarys (for Friedreich's ataxia) grew roughly 31% and Zurzuvae (for postpartum depression) advanced sequentially. The company's shares gained sharply after its most recent earnings report, helped by 2026 earnings guidance that came in above analyst expectations. Management is emphasizing its "Fit for Growth" cost discipline and an expanding late-stage pipeline, including programs in lupus and Alzheimer's disease, as the foundation for a longer-term transition away from its shrinking legacy business.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates the platform's top-performing AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they monitor, allowing users to align a bot's approach with their own objectives and risk tolerance. By surfacing only the strongest current performers, the page helps simplify the process of identifying automated strategies worth closer review. Explore the Trending AI Robots to see which automated approaches are leading the field today.
Head-to-Head Comparison
The clearest contrast between these two stocks lies in scale and trajectory. Amgen operates a much larger, more diversified revenue base, which has allowed it to grow even as some franchises face biosimilar competition. Biogen, by comparison, is smaller and more concentrated in neuroscience, making its relative performance more sensitive to individual product cycles and clinical catalysts. On growth drivers, Amgen's near-term story centers on commercial execution and the MariTide readout, while Biogen's hinges on new-product launches and pipeline outcomes in Alzheimer's and lupus. Risk profiles also differ: Amgen faces broad pricing and patent-exposure dynamics across a wide portfolio, whereas Biogen carries the concentrated risk of its legacy MS decline and binary clinical events. From a sentiment standpoint, Amgen benefits from consistent earnings beats and a long dividend-growth record, while Biogen trades at a valuation discount and offers greater catalyst-driven upside.
Tickeron AI Verdict
Based on observable factors such as trend consistency, portfolio stability, and relative positioning, Tickeron's AI would likely favor AMGN in the current environment. Amgen's broader revenue base, sustained double-digit growth, and more stable earnings trajectory present a steadier, lower-variance profile than Biogen's still-evolving transition. That said, the assessment is probabilistic rather than definitive: BIIB offers meaningful optionality tied to its Alzheimer's and lupus pipeline, which could shift the relative ranking if key catalysts land favorably. Investors should weigh Amgen's consistency against Biogen's higher-risk, higher-optionality positioning when interpreting this comparison.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and BIIB is a Hold.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 47 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 189 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.689) is normal, around the industry mean (-3.019). P/E Ratio (27.576) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.041) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
BIIB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 39 of 60 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 50 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 166 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 122 of 197 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.990) is normal, around the industry mean (-3.019). P/E Ratio (44.690) is within average values for comparable stocks, (21.251). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 100 | |
SMR RATING 1..100 | 15 | 84 | |
PRICE GROWTH RATING 1..100 | 7 | 6 | |
P/E GROWTH RATING 1..100 | 25 | 3 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (80) in the Biotechnology industry is in the same range as BIIB (80). This means that AMGN’s stock grew similarly to BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (5) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for BIIB (84). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (6) in the Biotechnology industry is in the same range as AMGN (7). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as AMGN (25). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 54% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 50% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 65% |
| Advances ODDS (%) | 8 days ago 61% | 3 days ago 59% |
| Declines ODDS (%) | 4 days ago 47% | 15 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 47% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- BIIB’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +3.05% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +7.86% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.32%. For the same industry, the average monthly price growth was -5.34%, and the average quarterly price growth was +5.08%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
BIIB is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.32% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +5.34% | ||
| AZN - BIIB | 49% Loosely correlated | +2.45% | ||
| AMGN - BIIB | 48% Loosely correlated | +2.04% | ||
| PFE - BIIB | 48% Loosely correlated | +1.91% | ||
| MRK - BIIB | 46% Loosely correlated | -1.76% | ||
| ABBV - BIIB | 41% Loosely correlated | +0.14% | ||
More | ||||